ASA: Alteplase Ups Outcomes at 4.5 to 24 Hours After Symptom Onset in Acute Ischemic Stroke
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 18, 2025 -- For patients with acute ischemic stroke (AIS) whose symptoms began 4.5 to 24 hours earlier, alteplase is associated with a higher percentage of patients achieving a score of 0 or 1 on the modified Rankin scale at 90 days, according to a study presented at the annual American Stroke Association International Stroke Conference, held from Feb. 5 to 7 in Los Angeles.
Min Lou, M.D., Ph.D., from the Second Affiliated Hospital of Zhejiang University School of Medicine in China, and colleagues conducted a prospective, randomized trial at 26 stroke centers in China involving patients with clinical signs of AIS within 4.5 and 24 hours and salvageable tissue on perfusion imaging. Patients were randomly assigned to receive intravenous alteplase or standard medical treatment (186 participants in both groups). The primary outcome was a score of 0 or 1 on the modified Rankin scale at 90 days.
Less than 3 percent of patients underwent endovascular thrombectomy (three and seven in the alteplase and standard medical treatment groups, respectively). The researchers found that the percentage of patients achieving a primary outcome was 40.3 and 26.3 percent in the alteplase and standard medical treatment groups, respectively (relative rate, 1.40; 95 percent confidence interval, 1.05 to 1.87). Mortality at 90 days was 10.8 percent with both alteplase and standard medical treatment, while the incidence of symptomatic intracerebral hemorrhage was 3.8 and 0.5 percent, respectively, within 36 hours after randomization.
"We believe these findings mean more people may return to normal or near-normal lives after a stroke, even if they receive treatment later than originally thought beneficial," Lou said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Use of Vaginal Estradiol Tablets Not Linked to Recurrent Stroke
THURSDAY, Aug. 21, 2025 -- For women with a history of ischemic stroke, use of vaginal estradiol tablets is not associated with an increased rate of recurrent stroke, according to...
Seniors With Certain Cardiovascular Diseases Saw Life's Essential 8 Scores Decline 2013 to 2018
WEDNESDAY, Aug. 20, 2025 -- From 2013 to 2018, older adults with heart failure, stroke, and hypertension experienced significant declines in Life's Essential 8 (LE8) scores...
Two Doses of Zoster Vaccine Reduce Risk for Herpes Zoster Ophthalmicus
TUESDAY, Aug. 19, 2025 -- Two doses of recombinant zoster vaccine (RZV) are associated with a reduced risk for herpes zoster ophthalmicus (HZO), acute myocardial infarction, and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.